Miao F, Ren G, Guo J, Zhao L, Xu W, Huang X. Characteristics of engraftment syndrome following autologous stem cell transplantation in light chain amyloidosis with renal involvement. Transplant Cell Ther. 2023;29:110.e1–110.e8.

Article  PubMed  Google Scholar 

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85–93.

Article  CAS  PubMed  Google Scholar 

Gatt ME, Palladini G. Light chain amyloidosis 2012: a new era. Br J Haematol. 2013;160:582–98.

Article  CAS  PubMed  Google Scholar 

D’Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. J Clin Oncol. 2015;33:3741–9.

Article  PubMed  PubMed Central  Google Scholar 

Leung N, Slezak JM, Bergstralh EJ, Dispenzieri A, Lacy MQ, Wolf RC, et al. Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. Am J Kidney Dis. 2005;45:102–11.

Article  CAS  PubMed  Google Scholar 

Nader R, Zhen A, Angel-Korman A, Pavlovich SS, Pogrebinsky A, Doros G, et al. Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis. Nephrol Dial Transplant. 2022;37:1281–8.

Article  CAS  PubMed  Google Scholar 

Leung N, Kumar SK, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, et al. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrol Dial Transplant. 2016;31:1284–9.

Article  CAS  PubMed  Google Scholar 

Bleeker JS, Gertz MA, Pellikka PA, Larson DR, Buadi F, Dingli D, et al. Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. Eur J Haematol. 2012;89:228–35.

Article  CAS  PubMed  Google Scholar 

Havasi A, Stern L, Lo S, Sun F, Sanchorawala V. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2016;91:E458–60.

Article  PubMed  PubMed Central  Google Scholar 

Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005;1753:11–22.

Article  CAS  PubMed  Google Scholar 

Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant. 2009;24:3132–7.

Article  CAS  PubMed  Google Scholar 

Li T, Huang X, Wang Q, Zhao L, Ren G, Chen W, et al. A risk stratification for systemic immunoglobulin light-chain amyloidosis with renal involvement. Br J Haematol. 2019;187:459–69.

Article  CAS  PubMed  Google Scholar 

Huang X, Ren G, Chen W, Guo J, Zhao L, Zeng C, et al. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients. Amyloid. 2021;28:75–83.

Article  CAS  PubMed  Google Scholar 

Andronesi AG, Tanase AD, Sorohan BM, Craciun OG, Stefan L, Varady Z, et al. Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma. Cancer Med. 2019;8:3278–85.

Article  PubMed  PubMed Central  Google Scholar 

Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M, et al. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney Int. 2003;63:1868–73.

Article  PubMed  Google Scholar 

Irazabal MV, Eirin A, Gertz MA, Dispenzieri A, Kumar S, Buadi FK, et al. Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. Am J Hematol. 2012;87:51–4.

Article  CAS  PubMed  Google Scholar 

Tamaki M, Nakasone H, Gomyo A, Hayakawa J, Akahoshi Y, Harada N, et al. Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan. Int J Hematol. 2018;108:423–31.

Article  CAS  PubMed  Google Scholar 

Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319–28.

Article  PubMed  Google Scholar 

Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–84.

Article  PubMed  Google Scholar 

Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9.

Article  CAS  PubMed  Google Scholar 

Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325–32.

Article  CAS  PubMed  Google Scholar 

Huang X, Fu C, Chen L, Chen W, Ren G, Guo J, et al. Combination of bortezomib in the induction, conditioning and consolidation with autologous hematopoietic stem cell transplantation in patients with immunoglobulin light chain amyloidosis. Am J Hematol. 2019;94:E101–e4.

Article  PubMed  Google Scholar 

Shimizu Y, Hirai T, Ogawa Y, Yamada C, Kobayashi E. Characteristics of risk factors for acute kidney injury among inpatients administered sulfamethoxazole/trimethoprim: a retrospective observational study. J Pharm Health Care Sci. 2022;8:20.

Article  PubMed  PubMed Central  Google Scholar 

Slater MB, Gruneir A, Rochon PA, Howard AW, Koren G, Parshuram CS. Identifying High-Risk Medications Associated with Acute Kidney Injury in Critically Ill Patients: A Pharmacoepidemiologic Evaluation. Paediatr Drugs. 2017;19:59–67.

Article  PubMed  Google Scholar 

Zavras P, Su Y, Fang J, Stern A, Gupta N, Tang Y, et al. Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study. Biol Blood Marrow Transplant. 2020;26:1482–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lilly CM, Welch VL, Mayer T, Ranauro P, Meisner J, Luke DR. Evaluation of intravenous voriconazole in patients with compromised renal function. BMC Infect Dis. 2013;13:14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Melphalan. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

Alix JL, Swiercz P, Schaerer R, Mousseau M, Cordonnier D, Couderc P.et al. [Nephrotoxicity of high-dose melphalan]. Presse Med. 1983;12:575–6.

Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant. 2005;35:971–7.

Article  CAS  PubMed  Google Scholar 

Abidi MH, Agarwal R, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, et al. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol Blood Marrow Transplant. 2013;19:56–61.

Article  CAS  PubMed  Google Scholar 

Gutiérrez-García G, Rovira M, Magnano L, Rosiñol L, Bataller A, Suárez-Lledó M, et al. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018;53:1541–7.

Article  PubMed  Google Scholar 

Liu Z, Zhang S, Horn B, Moreb JS. Postautologous stem cell transplantation engraftment syndrome: Improved treatment and outcomes. Clin Transplant. 2020;34:e13797.

Article  PubMed  Google Scholar 

McCoy IE, Chertow GM. AKI-A Relevant Safety End Point? Am J Kidney Dis. 2020;75:508–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meyrier A, Niaudet P. Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int. 2018;94:861–9.

Article  PubMed  Google Scholar 

Parikh CR, Coca SG. Acute kidney injury: defining prerenal azotemia in clinical practice and research. Nat Rev Nephrol. 2010;6:641–2.

Article  PubMed  Google Scholar 

Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers. 2021;7:52.

Article  PubMed  Google Scholar 

Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, et al. Chronic kidney disease. Nat Rev Dis Primers. 2017;3:17088.

Article  PubMed  Google Scholar 

Joslin J, Wilson H, Zubli D, Gauge N, Kinirons M, Hopper A, et al. Recognition and management of acute kidney injury in hospitalised patients can be partially improved with the use of a care bundle. Clin Med (Lond). 2015;15:431–6.

Article